4DMedical (ASX:4DX) secured clearance from the US Food and Drug Administration for its IQ-UIP diagnostic tool, according to a Tuesday filing with the Australian bourse.
The product was designed to identify the presence of usual interstitial pneumonia, which is used to detect interstitial pulmonary fibrosis, the filing said.
Company shares surged almost 16% in recent Tuesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.